Faron Pharmaceuticals Oy: Interim Results for the six months ended 30 June 2017
September 06, 2017 07:01 ET
|
Faron Pharmaceuticals Oy
Faron Pharmaceuticals Ltd("Faron" or the "Company") Interim Results for the six months ended 30 June 2017 INTEREST Phase III Traumakine® trial patient recruitment to complete in Q4 2017...
Faron Pharmaceuticals Oy: Faron announces that US FDA proposes proceeding directly to BLA submission for Traumakine® following completion of European and Japanese Phase III studies
September 04, 2017 07:12 ET
|
Faron Pharmaceuticals Oy
Faron Pharmaceuticals Ltd("Faron" or the "Company") Faron announces that US FDA proposes proceeding directly to BLA submission for Traumakine® following completion of European and Japanese Phase...
Faron Pharmaceuticals Oy: Final Results for the year ended 31 December 2016
March 29, 2017 11:13 ET
|
Faron Pharmaceuticals Oy
Faron Pharmaceuticals Ltd("Faron" or the "Company") Final Results for the year ended 31 December 2016 TURKU - FINLAND, 29 March 2017 Faron Pharmaceuticals Ltd ("Faron") (LON: FARN), the...